Evidence map›Paper›PMID 27002635›Full record

ReviewVirulence2016

Bloodstream infections in neutropenic cancer patients: A practical update.

Giulia Gustinetti, Malgorzata Mikulska

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Virulence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07372131 (Appropriate Management of Bacteriemic Febrile Neutropenia in High-Risk Hematological Patients. Relationship Between Duration of Antibiotic Administration, Outcome and Resistance Profile), which is not on this map. Cited by 108 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07372131 narecruitingnot on this mapstarted 2026, after this paper: background citation

Appropriate Management of Bacteriemic Febrile Neutropenia in High-Risk Hematological Patients. Relationship Between Duration of Antibiotic Administration, Outcome and Resistance Profile

TypeinterventionalSponsorValeria CentoRan2026 to 2028Enrolled172ConditionsBloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)ArmsClinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Enterococcal bacteremia in children with malignancy or after hematopoietic stem cell transplantation: real-world multicenter data from a nationwide survey in Poland (2014-2021).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Giulia Gustinettia Division of Infectious Diseases, University of Genova (DISSAL) and IRCCS San Martino-IST , Genova , Italy.
Malgorzata Mikulskaa Division of Infectious Diseases, University of Genova (DISSAL) and IRCCS San Martino-IST , Genova , Italy.
Ospedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bloodstream infections (BSI) are among the most frequent complications in neutropenic cancer patients and, if caused by Gram-negative rods, are associated with high mortality. Thus, fever during neutropenia warrants prompt empirical antibiotic therapy which should be active against the most frequent Gram-negatives. In the last decade, there has been a worldwide increase in multidrug resistant (MDR) strains. In these cases, the traditional choices such as oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, or even carbapenems, might be ineffective. Therefore novel de-escalation approach has been proposed for patients who are at high risk for infections due to MDR bacteria. It consists of starting antibiotics which cover the most probable resistant strain but it is narrowed down after 72 hours if no MDR pathogen is isolated. With increasing bacterial resistance, the benefit of fluoroquinolone prophylaxis during prolonged neutropenia remains to be confirmed. Antibiotic stewardship and infection control programs are mandatory in every cancer center.

Indexed as

Anti-Bacterial AgentsBacteremiaCefepimeCephalosporinsDisease ManagementDrug Resistance, BacterialFebrile NeutropeniaFluoroquinolonesGram-Negative BacteriaHumansPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPre-Exposure ProphylaxisRisk FactorsAnti-Bacterial AgentsCefepimeCephalosporinsFluoroquinolonesPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug Combinationbloodstream infectionsde-escalationempirical treatmentfebrile neutropeniaMDR bacteriaoutpatient management

Identifiers

PMID27002635
PMCPMC4871679
OpenAlexW2310013765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.